A rhenium(I) tricarbonyl diimine complex with a N,N-dimethylformamide ligand captures one CO2 molecule in the presence of triethanolamine (TEOA), giving fac-[Re(I)(bpy)(CO)3{R2N-CH2CH2O-COO}] (bpy = 2,2'-bipyridine, R = CH2CH2OH). This could be a predominant complex in various photocatalytic CO2 reduction reactions using [Re(I)(N^N)(CO)3X](n+) (N^N = diimine ligand; X = monodentate ligand; n = 0, 1) type complexes in the presence of TEOA.

Detection of p53 mutations may help in the selection of NSCLC patients suitable for appropriate investigational therapeutic strategies in view of improving their survival and quality of life.

RESULTS. Thirty-one of 115 NSCLC specimens (27%) showed negative p16 staining. Department of Surgery II, School of Medicine,The frequency of negative p16 expression was significantly higher in squamous University of Occupational and Environmental cell carcinoma (39.5%) than in adenocarcinoma (20.3%) (P Å 0.026). There were Health, Kitakyushu, Japan.no statistically significant differences in the p16 status with respect to age, gender, smoking history, histologic differentiation, or stage of the disease. The KaplanMeier survival curves demonstrated that patients with negative p16 expression survived for a significantly shorter period of time than those with positive p16 expression (P Å 0.043). p16 status was a significant prognostic factor, especially in patients with early stage disease (Stages I-II) (P Å 0.039). CONCLUSIONS.A lack of p16 INK4 expression in NSCLC was observed more frequently in squamous cell carcinoma than in adenocarcinoma, and also was found to be closely related to prognosis, especially in patients with early stage squamous cell carcinoma.

We examine serum level of galectin-3 in patients with bladder cancer. We used serum samples of 67 patients with urological diseases and classified these patients into bladder cancer group (n=43) and control group (n=24). Galectin-3 concentration was measured by ELISA (Human Galectin-3 Assay Kit, IBL). And we selected the patient with high serum galectin-3 concentration (Urothelial Carcinoma, G3, pT3a pN0M0), we performed immunohistochemical staining with the VECTASTAIN ABC (Avidin Biotinylated enzyme Complex) system. Median value of serum galectin-3 concentration was 1068 pg/ml (range 551-2028) in the cancer group vs 584 pg/ml (range 259-1262) in controls. Serum galectin-3 concentration of the bladder cancer patients was statistically higher than that of controls (p<0.0005). There was no apparent correlation in serum galectin-3 concentration with the clinico-pathological features such as stage and grade. Higher expression of galectin-3 was observed in bladder cancer tissue than in normal bladder tissue. We suggest the measurement of serum galectin-3 is useful for diagnosis of bladder cancer.

No abstract